As CALM-AF10 and SET-NUP214 leukemias are characterized by HOXA9-overexpression and dependency on the HOXA9 pathway, we tested for differences in baseline expressions of HOXA9 and MEIS1 between CCI-007 sensitive and resistant leukemia cells, but could not detect any significant differences indicating that the compound does not simply target HOXA9/MEIS1 overexpressing leukemia cells as such. This evidence concerns the gene HOXA9 and leukemia.